Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check10 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check67 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check82 days agoChange DetectedThe page has undergone significant content changes, particularly the removal of detailed descriptions of a clinical study on pancreatic cancer, including its design and inclusion/exclusion criteria. Additionally, a new version number has been added, indicating an update to the document.SummaryDifference18%
Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.